Topical 0.5% ketorolac vs 0.03% flurbiprofen for inhibition of miosis during cataract surgery

Archives of Ophthalmology

Volumn 115, Issue 9, 1997, Pages 1119-1122

  Solomon, Kerry D ^a,b   Turkalj, Judy Wang ^a   Wlnteside, Stephen B ^a   Stewart, Jeanette A ^a   Apple, David J ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLURBIPROFEN; KETOROLAC TROMETAMOL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HUMAN; LENS IMPLANT; MAJOR CLINICAL STUDY; MIOSIS; PATIENT COMPLIANCE; PHACOEMULSIFICATION; POSTOPERATIVE CARE; PREOPERATIVE CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUPIL; RANDOMIZED CONTROLLED TRIAL; TOPICAL DRUG ADMINISTRATION;

EID: 0030885286     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.1997.01100160289004     Document Type: Article

References (48)

1. Girard LJ, Hawkins RS. Cataract extraction by ultrasonic aspiration: vitrectomy by ultrasonic aspiration. Trans Am Acad Ophthalmol Otolaryngol. 1974;78:50-59.
2. Freeman JM, Gettelfinger TC. Maintaining pupillary dilatation during lens implant surgery. Am Intra-Ocular Implant Soc J. 1981;7:172-173.
3. Podos SM. Prostaglandins, nonsteroidal anti-inflammatory agents and eye disease. Trans Am Ophthalmol Soc. 1976;74:637-660.
4. Keates RH, McGowan KA. Clinical trial of flurbiprofen to maintain pupillary dilation during cataract surgery. Ann Ophthalmol. 1984;16:919-921.
5. Hiilman JS, Frank GJ, Kheskan MB. Flurbiprofen and human intraocular inflammation. Adv Prostag/andin Thromboxane Res. 1980;1723-1725.
6. Bhattacherjee P, Eakins KE. Inhibition of the prostaglandin synthetase systems in ocular tissues by indomethacin. Br J Pharmacol. 1974:50:227-230.
7. Ambache N, Brummer HC. A simple chemical procedure for distinguishing E from F prostaglandins with application to tissue extracts. Br J Pharmacol. 1968;33:162-170.
8. Ambache N, Kavanagh L, Whiting J. Effect of mechanical stimulation on rabbits' eyes: release of active substance in anterior chamber perfusâtes. JPhysiol. 1965; 176:378-408.
9. Anggard E, Samuelsson B. Smooth muscle stimulating lipids in sheep iris: the identification of prostaglandin F22. Biochem Pharmacol. 1964;13:281-283.
10. Cole DF, linger WG. Prostaglandins as mediators for the responses of the eye to trauma. Exp Eye Res. 1973:17:357-368.
11. Eakins KE. Prostaglandin and non-prostaglandin mediated breakdown of the bloodaqueous barrier. Exp Eye Res. 1977;25(suppl):483-498.
12. Neufeld AH, Sears ML. Prostaglandin and eye. Prostaglandins. 1973:4:157175.
13. Podos SM, Becker B, Kass MA. Prostaglandin synthesis, inhibition, and intraocular pressure. Invest Ophthalmol Vis Sei. 1973:12:426-433.
14. Wafeman MB, King CD. Prostaglandin influences on intraocular pressure and pupil size. Am J Physiol. 1967;212:329-334.
15. Gregersen PL, Nielsen PJ, Mortensen KK. The effect of indomethacin 1% ophthalmic suspension on the pupil during extracapsular cataract surgery. Acta Ophthalmol. 1992:70:522-524.
16. Sawa M, Masuda K. Topical indomethacin in soft cataract aspiration. Jpn JOphthalmol. 1976:20:514-519.
17. Duke-Elder PM, Duke-Elder WS. The vascular responses of the eye. Proc R Soc LonrJ B Biol Sei. 1931 ;109B:19-28.
18. Bhattacherjee P, Eakins KE. A comparison of the inhibitory activity of compounds on ocular prostaglandin biosynthesis. Invest Ophthalmol Vis Sei. 1974: 13:967-972.
19. Podos SM, Becker B. Comparison of ocular prostaglandin synthesis inhibitors. Invest Ophthalmol Vis Soi. 1976;15:841-844.
20. Klug RD, Krohn DL, Breitfeller JM, Dietrich D. Inhibition of trauma-induced miosis by indoxole. Ophthalmic Res. 1981 ;13:122-128.
21. Neufeld AH, Jampol LM, Sears ML. Aspirin prevents the disruption of the bloodaqueous barrier in the rabbit eye. Nature. 1972:238:158-159.
22. Ballas 2, Blumenthal M, Tinkelman DG, Kriz R, Rupp G. Clinical evaluation of ketorolac tromethamine 0.5% ophthalmic solution for the treatment of seasonal allergic conjunctivitis. Sun Ophthalmol. 1993;38(suppl):141-148.
23. Tinkelman DG, Rupp G, Kaufman H, Pugely J, Schultz N. Double-masked, pairedcomparison clinical study of ketorolac tromethamine 0.5% ophthalmic solution compared with placebo eyedrops in the treatment of seasonal allergic conjunctivitis. Surv Ophthalmol. 1993;38(suppl):133-140.
24. Flach AJ, Dolan BJ, Irvine AR. Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema. Am J Ophthalmol. 1987;103:479-486.
25. Flach AJ, Jampol LM, Weinberg D, et al. Improvement of visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. Am J Ophthalmol. 1991 ;112:514-519.
26. Räch AJ, Stegman RC, Graham J, Kluger LP. Prophylaxis of aphakic cystoid macular edema without corticosteroids: a paired-comparison, placebo-controlled doublemasked study. Ophthalmology. 1990:97:1253-1258.
27. Stark WJ, Fagadau WR, Stewart RH, et al. Reduction of pupillary constriction during cataract surgery using suprofen. Arch Ophthalmol. 1986:104:364-366.
28. Miyake K, Sugiyama S, Norimatsu I, OzawaT. Prevention of cystoid macular edema after lens extraction by topical indomethacin, III: radioimmunoassay measurement of prostaglandins in the aqueous during and after lens extraction procedures. GraefesArch Clin Exp Ophthalmol. 1978:209:83-88.
29. Kremer M, Baikoff G, Charbonnel B. Prostaglandin E2 in side effects of ocular surgery in man: preventive action of indomethacin. Adv Prostaglandin Thromboxane Leukot Res. 1983;12:121-126.
30. Kulkarni PS, Eakins HMT, Saber WL, et al. Microsomal preparations of normal bovine iris-ciliary body generate prostacyclin-like but not thromboxane-A2 activity. Prostag/andins. 1977:14:689-700.
31. Kulkarni PS. Synthesis of cyclooxygenase products by human anterior uvea from cyclic prostaglandin endoperoxide (PGH2). Exp Eye Res. 1981:32:197-204.
32. Bhattacherjee P, Eakins KE. Inhibition of the ocular effects of sodium arachidonate by anti-inflammatory compounds. Prostaglandins. 1975:9:175-182.
33. Nozu K. Flurbiprofen: highly potent inhibitor of prostaglandin synthesis. Biochim BiophysActa. 1978:529:493-496.
34. Arshinoff S, D'Addario D, Sadler C, Bilotta R, Johnson TM. Use of topical nonsteroidal anti-inflammatory drugs in excimer laser photorefractive keratectomy. J Cataract Refract Surg. 1994:20:216-222.
35. Cherry PM, Tutton MK, Adhikary H, et al. The treatment of pain following photorefractive keratectomy. J Refract Corneal Surg. 1994;10(suppl):S222-S225.
36. Keates RH, McGowan KA. The effect of topical indomethacin ophthalmic solution in maintaining mydriasis during cataract surgery. Ann Ophtha/mol. 1984; 16:1116-1121.
37. Keulen-De Vos HCJ, Van Rij G, Renardel de Lavalette JCG, Jansen JTG. Effect of indomethacin in preventing surgically induced miosis. Br J Ophthalmol. 1983; 67:94-96.
38. Nielsen PJ, Gregersen P, Mortensen KK, Kalstrup N. The effect of indomethacin 1 % ophthalmic suspension in preventing surgically induced miosis at extracapsular cataract surgery. Acta Ophthalmol. 1987;65(suppl 182):115-118.
39. Rooks WH II, Tomolonis AJ, Maloney PJ, Wallach MB, Schuler ME. The analgesic and anti-inflammatory profile of -5;benzoyl-1,2-dihydro-3Hpyrrolo[1,2a]pyrro!e-1-carboxy!ic acid (RS-37619). Agents Actions. 1982;12: 684-690.
40. Flach AL. Cyclo-oxygenase inhibitors in ophthalmology. Surv Ophthalmol. 1992; 36:259-284.
41. Rooks WH II, Maloney PJ, Short LD, et al. The analgesic and anti-inflammatory profile of ketorolac and its tromethamine salt. Drugs Exp Clin Res. 1985;11:479492.
42. Ling TL, Combs DL Ocular bioavailability and tissue distribution of [14C]ketorolac tromethamine in rabbits. J Pharm Sei. 1987;76:289-294.
43. Rooks WH II. The pharmacologie activity of ketorolac tromethamine. Pharmacotherapy. 1990;10:30S-32S.
44. MahoneyJM, Waterbury LD. -5-benzoyl-1,2-dihydro-3H-pyrrolo[1,2a]pyrrole1 -carboxylic acid (RS-37619): a non-irritating ophthalmic anti-inflammatory agent. Invest Ophthalmol Vis Sei. 1983;24(suppl):151A.
45. Flach AJ, Graham J, Kruger LP, Stegman RC, Tanenbaum L. Quantitative assessment of postsurgical breakdown of the blood-aqueous barrier following administration of 0.5% ketorolac tromethamine solution: a double-masked, paired comparison with vehicle-placebo solution study. Arch Ophtha/mol. 1988:106: 344-347.
46. Flach AJ, Kraff MC, Sanders DR, Tanenbaum L The quantitative effect of 0.5% ketorolac tromethamine solution and 0.1% dexamethasone sodium phosphate solution on postsurgical blood-aqueous barrier. Arch Ophtha/mol. 1988:106: 480-483.
47. Seitz B, Sorken K, LaBree LD, Garbus JJ, McDonnell PJ. Corneal sensitivity and burning sensation: comparing topical ketorolac and diclofenac. Arch Ophthalmol. 1996:114:921-924.
48. Flach AJ, Lavelle CJ, Olander KW, Retzlaff JA, Sorenson LW. The effect of ketorolac tromethamine solution 0.5% in reducing postoperative inflammation after cataract extraction and intraocular lens implantation. Ophthalmology. 1988; 95:1279-1284.